In one paragraphArticle in Journal of natural products, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Patrik F SchwarzDepartment of Pharmaceutical Sciences, Division of Pharmacognosy, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0002-3093-4176 Alexander F PerhalDepartment of Pharmaceutical Sciences, Division of Pharmacognosy, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0003-3922-6333 Famke GuderInstitute of Genetics and Molecular and Cellular Biology, University of Strasbourg, CNRS UMR7104, INSERM U 1258, Illkirch-Graffenstaden, 67404, France.
Jorge Enrique Hernández GonzálezDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0002-4770-8677 Kerrin JanssenDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0001-8661-2750 Ece SağıroğluDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0009-0008-4997-307X Ammar TahirDepartment of Pharmaceutical Sciences, Division of Pharmacognosy, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0003-3682-5680 Johannes KirchmairDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0003-2667-5877 Natacha RochelInstitute of Genetics and Molecular and Cellular Biology, University of Strasbourg, CNRS UMR7104, INSERM U 1258, Illkirch-Graffenstaden, 67404, France.ORCID 0000-0002-3573-5889 Verena M DirschDepartment of Pharmaceutical Sciences, Division of Pharmacognosy, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0002-9261-5293 Ya ChenDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0001-5273-1815 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Targeting retinoic acid-related orphan receptor γ (RORγ) with inverse agonists presents a promising therapeutic strategy for treating autoimmune diseases, including psoriasis, rheumatoid arthritis, and multiple sclerosis. Through structure-based virtual screening, we identified a lupane-type pentacyclic triterpenoid, (2Z)-2-(2-furanylmethylene)-3-oxolup-20(29)-en-28-oic acid (
Indexed as
Nuclear Receptor Subfamily 1, Group F, Member 3Pentacyclic TriterpenesTriterpenesBetulinic AcidDrug Inverse AgonismHumansLupanesMolecular StructureStructure-Activity RelationshipBetulinic AcidlupaneLupanesNuclear Receptor Subfamily 1, Group F, Member 3Pentacyclic TriterpenesTriterpenes
Identifiers
PMID40720698
PMCPMC12379159
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390